Projects

Mgr. Michal Šelc, PhD.

International

Finished
  • Epigenotoxicity of nanomaterials
    Program: Inter-academic agreement
    Duration: 1. 1. 2020 – 31. 12. 2022

National

Finished
  • Novel renal antisense therapy platform for CKD
    Program: SRDA
    Duration: 1. 8. 2021 – 30. 6. 2025
  • Diagnostic of oncological diseases using aptasensors: development and validation
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Preclinical validation of an innovative antisense platform for CML
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Preclinical validation of a SARS-CoV-2-specific RNA inhibitor
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2024
  • Targeted inhibition of SARS-CoV-2 by a new generation RNA inhibitor
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Gold nanoparticles: impact of physicochemical properties on distribution, accumulation, and biological response in vivo (BIONANOGOLD)
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Multivalent morpholino-based antisense system for CML
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Antioxidative, anticarcinogen and photoprotective effects of the essential oil from lavender in vitro.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Mechanisms of gold and magnetic nanoparticle effects on renal cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Mechanism of uptake and trafficking of magnetic iron oxide nanoparticles into human tumor and normal (diploid) cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
Employees